July 19, 2021

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549-7561

Ladies and Gentlemen:

We have read Vaxart, Inc.'s statements included under Item 4.01 of its Form 8‑K dated July 19, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K.

Very truly yours,

/s/ OUM & Co. LLP

Attachments

  • Original document
  • Permalink

Disclaimer

Vaxart Inc. published this content on 20 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2021 10:03:10 UTC.